Identification of ALK, ROS1, and RET fusions by a multiplexed mRNA-based assay in formalin-fixed, paraffin-embedded samples from advanced non-small-cell lung cancer patients

Clinical Chemistry

Volumn 63, Issue 3, 2017, Pages 751-760

  Reguart, Noemí ^a   Teixidó, Cristina ^b   Giménez Capitán, Ana ^b   Paré, Laia ^a   Galván, Patricia ^a,b,c   Viteri, Santiago ^b   Rodríguez, Sonia ^b   Peg, Vicente ^b   Aldeguer, Erika ^b   Viñolas, Nuria ^a   Remon, Jordi ^d   Karachaliou, Niki ^b,e   Conde, Esther ^f   Lopez Rios, Fernando ^f   Nadal, Ernest ^g   Merkelbach Bruse, Sabine ^h   Büttner, Reinhard ^h   Rosell, Rafael ^b,g   Molina Vila, Miguel A ^b   Prat, Aleix ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^f Hospital Universitario Madrid Sanchinarro   (Spain)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EZRIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; K RAS PROTEIN; KINESIN 5; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN RET; PROTEIN TYROSINE KINASE; ROS PROTOONCOGENE 1 RECEPTOR TYROSINE KINASE; SODIUM PHOSPHATE COTRANSPORTER 2B; UNCLASSIFIED DRUG; FORMALDEHYDE; MESSENGER RNA; ONCOPROTEIN; PARAFFIN; ROS1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; ARTICLE; ASSAY; CANCER PATIENT; CLINICAL OUTCOME; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; N COUNTER ASSAY; NON SMALL CELL LUNG CANCER; OLIGONUCLEOTIDE PROBE; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PURIFICATION; SENSITIVITY AND SPECIFICITY; GENETICS; LUNG TUMOR; METABOLISM; TISSUE FIXATION; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; PARAFFIN EMBEDDING; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE FIXATION;

EID: 85014439476     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.265314     Document Type: Article

References (37)

1. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
2. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363: 1693-703.
3. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006.
4. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
5. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81.
6. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012;22:2109-19.
7. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-7.
8. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012;22:436-45.
9. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131: 1190-203.
10. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68: 3389-95.
11. Watson AJ, Hopkins GV, Hitchin S, Begum H, Jones S, Jordan A, et al. Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade. F1000Res 2016;5:1005.
12. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALKpositive lung cancer. N Engl J Med 2013;368:2385-94.
13. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371: 2167-77.
14. FDA. Summary of safety and effectiveness data (SSED). 2015. www.accessdata.fda.gov/cdrh-docs/pdf10/p100034b.pdf (Accessed July 2016).
15. Dagogo-Jack I, Shaw AT. Screening for ALK rearrangements in lung cancer: time for a new generation of diagnostics? Oncologist 2016;21:662-3.
16. Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012;18:6599-608.
17. Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn 2013;15:51-61.
18. Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, et al. A single-tube multiplexed assay for detecting ALK, ROS1 and RET fusions in lung cancer. J Mol Diagn 2014;16:229-43.
19. Lee SE, Lee B, Hong M, Song JY, Jung K, Lira ME, et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod Pathol 2015;28: 468-79.
20. Sunami K, Furuta K, Tsuta K, Sasada S, Izumo T, Nakaoku T, et al. Multiplex diagnosis of oncogenic fusion and met exon skipping by molecular counting using formalin-fixed paraffin embedded lung adenocarcinoma tissues. J Thorac Oncol 2016;11:203-12.
21. Costa C, Molina MA, Drozdowskyj A, Gimenez-Capitan A, Bertran-Alamillo J, Karachaliou N, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res 2014;20:2001-10.
22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33: 159-74.
23. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
24. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS-1 rearranged nonsmallcell lung cancer. N Engl J Med 2014;371:1963-71.
25. Mazieres J, Zalcman G, Crino L, Biondani P, Barlesi F, Filleron T, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 2015;33:992-9.
26. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013;3:630-5.
27. Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion patternspecific clinicopathologic, histologic and cytologic features. Lung Cancer 2014;84:121-6.
28. Farragher SM, Tanney A, Kennedy RD, Paul Harkin D. RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol 2008;130:435-45.
29. Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, et al. Differential crizotinib response duration among ALK fusion variants in ALK-positive non-smallcell lung cancer. J Clin Oncol 2016;34:3383-9.
30. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-24.
31. Seto T, Yoh K, Satouchi M, Nishio M, Yamamoto N, Murakami H, et al. A phase II open-label single-arm study of vandetanib in patients with advanced RETrearranged non-small cell lung cancer (NSCLC): LURET study. J Clin Oncol 2016;34(suppl):abstr 9012.
32. Marchetti A, Di Lorito A, Pace MV, Iezzi M, Felicioni L, D'Antuono T, et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol 2016;11:487-95.
33. Pyo JS, Kang G, Sohn JH. ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis. Int J Biol Markers [Epub ahead of print 2016 Jun 16].
34. Takeuchi K, Togashi Y, Kamihara Y, Fukuyama T, Yoshioka H, Inoue A, et al. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol 2016;27:185-92.
35. Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. Oncologist 2016;21:762-70.
36. Rosoux A, Pauwels P, Duplaquet F, D'Haene N, Weynand B, Delos M, et al. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma. Lung Cancer 2016;98: 118-21.
37. Shan L, Lian F, Guo L, Qiu T, Ling Y, Ying J, Lin D. Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RTPCR. PLoS One 2015;10:e0120422.